RINVOQ

Prolonged-release tablet, 15mg
RxActive license

Active substance (INN)

upadacitinib

Pharmaceutical form

Pharmaceutical formProlonged-release tablet
Strength15mg
PackagingUkupno 28 tableta sa produženim oslobađanjem u blisteru (4x7) u kartonskoj kutiji
ManufacturerAbbVie Logistics B.V., Netherlands
Therapeutic groupAntineoplastic and immunomodulating agents (L04AF03)
Marketing authorization holderDRUŠTVO ZA TRGOVINU NA VELIKO FARMACEUTSKIM PROIZVODIMA "GLOSARIJ" D.O.O.-PODGORICA
Authorization dateSeptember 24, 2020

Analogs in Montenegro

2

Other medicines with the same active substance

RINVOQRx
Prolonged-release tablet, 30mgAbbVie Logistics B.V.
RINVOQRx
Prolonged-release tablet, 45mgAbbVie Logistics B.V.
Source: CInMED register